Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer
Status:
Unknown status
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This study evaluates the relationship of biomarker expression and efficacy of bevacizumab
plus chemotherapy in patients with unresectable/metastatic colorectal cancer. Before the
treatment, the investigators detect the VEGF-A,VEGF-C,VEGF-D,VEGFR-1,VEGFR-2,VEGFR-3
expression in tumor tissue by IHC and detect those protein expression level in plasma by
ELISA. After at least 6 weeks treatment, the investigators detect again VEGF-A,VEGF-C,VEGF-D
expression level in plasma by ELISA. The aim of the study is to identify whether those
biomarkers could predict Bevacizumab efficacy.